Roche Reported Success in Phase 3 Kidney Trial
The company's investigational drug sefaxersen met its primary endpoint in a study treating patients with IgA nephropathy.
Updated on Sept. 23, 2026 in Biotech
Live Poll
Should government prioritize the approval of high-cost specialty drugs over lower-cost existing treatment alternatives?
Roche announced that its phase 3 Imagination study of sefaxersen reached its primary goal during an interim analysis at Week 37. Patients treated with monthly injections of the drug showed significant reductions in proteinuria compared to those receiving a placebo.
Why it matters
High levels of complement factor B contribute to cellular damage in IgA nephropathy, and successfully inhibiting this protein could provide a new therapeutic option for patients. The positive result supports Roches strategy of targeting specific biological pathways to address complex kidney disease.
The Imagination study evaluated monthly subcutaneous injections of sefaxersen, which functions as an antisense oligonucleotide that inhibits complement factor B production. Researchers measured efficacy by tracking changes in the 24-hour protein-to-creatinine ratio.
The players
Roche
Based in Switzerland, this multinational healthcare company focuses on pharmaceutical and diagnostic research.
Ionis Pharmaceuticals
This biotechnology firm specializes in discovering and developing antisense oligonucleotide therapies.
GSK
This global biopharmaceutical company previously held rights to the sefaxersen program before exiting in 2017.
The details
Sefaxersen aims to manage IgA nephropathy by reducing the complement factor B levels that drive kidney cell destruction. Following this successful interim analysis, Roche intends to enter discussions with regulatory authorities to determine pathways for accelerated approval.
Timeline
In 2017, GSK abandoned the development program.
Roche secured an option on the asset for $75 million in 2018.
The company licensed the drug for $55 million upfront in 2022.
Trial results met the primary endpoint at the Week 37 interim analysis.
The Tech Race
The development of sefaxersen represents an ongoing effort to refine precision therapies for kidney disease by targeting specific genetic and protein pathways. This aligns with a broader industry shift toward specialized biological treatments that challenge the dominance of earlier, less targeted pharmaceutical interventions.
If approved, this therapy would offer patients with IgA nephropathy a new method for managing kidney damage via monthly subcutaneous injections. Analysts currently project that the drug could eventually generate between 1 billion and 2 billion euros in peak global sales.
The takeaway
The positive interim results highlight the continued success of antisense oligonucleotide technology in treating chronic autoimmune conditions. Roche remains positioned to expand its nephrology portfolio as it transitions the drug into final regulatory and long-term efficacy reviews.
What happens next
The Imagination study is scheduled to evaluate the long-term changes in patient kidney function at the Week 105 analysis.
Further reading
Learn more about the latest industry trends in the Biotech section.
Live Poll
Should government prioritize the approval of high-cost specialty drugs over lower-cost existing treatment alternatives?
